Identification of antidepressant drug leads through the evaluation of marine natural products with neuropsychiatric pharmacophores

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 1, 2008, Pages 46-53

  Diers, Jeffrey A ^a   Ivey, Kelly D ^a   El Alfy, Abir ^a   Shaikh, Jamaluddin ^a   Wang, Jiajia ^a   Kochanowska, Anna J ^a   Stoker, John F ^a   Hamann, Mark T ^a   Matsumoto, Rae R ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antidepressant; Forced swim test; Locomotor activity; Marine natural product; Selective serotonin reuptake inhibitor (SSRI); Tail suspension test (TST); Tricyclic antidepressant (TCA)

Indexed keywords

5,6 DIBROMO N,N DIMETHYLTRYPTAMINE; 8,9 NORAAPTAMINE; AAPTAMINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; ISOAAPTAMINE; MANZAMINE A; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG IDENTIFICATION; FORCED SWIMMING TEST; HYPERACTIVITY; IMMOBILIZATION STRESS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; SPONGE (PORIFERA); STRAIN DIFFERENCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOLOGICAL PRODUCTS; CITALOPRAM; DESIPRAMINE; DRUG EVALUATION, PRECLINICAL; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED DBA; MOTOR ACTIVITY; SWIMMING;

MUS;

EID: 38049153250     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.10.021     Document Type: Article

References (39)

1. Amsler C.D., McClintock J.B., and Baker B.J. Secondary metabolites as mediators of trophic interactions among Antarctic marine organisms. Am Zool 41 (2001) 17-26
2. Bai F., Li X., Clay M., Lindstrom T., and Skolnick P. Intra- and interstrain differences in models of "behavioral despair.". Pharmacol Biochem Behav 70 (2001) 187-192
3. Battershill C., Jaspars M., and Long P. Marine biodiscovery: new drugs from the ocean depths. Biologist 52 (2005) 107-114
4. Bourin M., Chenu F., Ripoll N., and David D.J.P. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension rests. Behav Brain Res 164 (2005) 266-269
5. Calcul L., Longeon A., Mourabit A., Guyot M., and Bourguet-Kondracki M. Novel alkaloids of the aaptamine class from an Indonesian marine sponge of the genus Xestospongia. Tetrahedron 59 (2003) 6539-6544
6. Coutinho A.F., Chanas B., Souza T.M.L., Frugrulhetti I.C.P.P., and Epifanio R.A. Anti HSV-1 alkaloids from a feeding deterrent marine sponge of the genus Aaptos. Heterocycles 57 (2002) 1265-1272
7. Crowley J.J., Blendy J.A., and Lucki I. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 183 (2005) 257-264
8. Crowley J.J., Brodkin E.S., Blendy J.A., Berrettini W.H., and Lucki I. Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 31 (2006) 2433-2442
9. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
10. Cryan J.F., Hoyer D., and Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54 (2003) 49-58
11. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacocological and genetic studies in mice. Neurosci Biobehav Rev 29 (2005) 571-625
12. Cryan J.F., Page M.E., and Lucki I. Differential behavior effects of the antidepressants reboxetine, flvoxetine, and moclobemide in a modified forced swim test following chronic treatment. J Psychopharmacol 182 (2005) 335-344
13. Diers J.A., Bowling J.J., Duke S.O., Wahyuono S., Kelly M., and Hamann M.T. Novel zebra mussel antifouling activity of the marine natural product aaptamine and analogs. Mar Biotechnol 8 (2006) 366-372
14. Djura P., Stierle D.B., Sullivan B., and Faulkner D.J. Some metabolites of the marine sponges Smenospongia aurea and Smenospongia (= Polyfibrospongia) echina. J Org Chem 80 (1980) 1435-1441
15. Gavagnin M., and Fontana A. Diterpenes from marine opisthobranch molluscs. Curr Org Chem 4 12 (2000) 1201-1248
16. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today 8 (2003) 536-544
17. 2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod 65 (2002) 476-480
18. Kulkarni S.K., and Ashish D. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry 31 6 (2007) 1248-1254
19. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., and Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40 (2001) 1028-1033
20. Liu X., and Gershenfeld H.K. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 49 (2001) 575-581
21. Maplestone R.A., Stone M.J., and Williams D.H. The evolutionary role of secondary metabolites - a review. Gene 115 (1992) 151-157
22. Matthews K., Christmas D., Swan J., and Sorrell E. Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev 29 (2005) 503-513
23. B receptors in the modulation of anxiety and antidepressant-like behavior. Neuropsychopharmacology 29 (2004) 1050-1062
24. Nestler E., Gould E., Manji H., Bucan M., Duman R., Gershenfeld H., et al. Preclinical models: status of basic research in depression. Biol Psychiatry 52 (2002) 503-528
25. Paul V.J. In: Paul V. (Ed). Ecological roles of marine natural products (1992), Comstock Publishing Associates, Ithica 1-23
26. Petit-Demouliere B., Chenu F., and Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 177 (2005) 245-255
27. Pettit G., Hoffmann H., Herald D., McNulty J., Murphy A., Higgs K., et al. Antineoplastic agents 491. Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine. J Org Chem 69 (2004) 2251-2256
28. Porsolt R., and Lenegre A. Behavioral models of depression. In: Eliott J., Heal D., and Mardesen C. (Eds). Experimental approaches to anxiety and depression (1992), Wiley, London 73-85
29. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
30. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn 229 (1977) 327-336
31. Rao K.V., Donia M.S., Peng J., Garcia-Palomero E., Alonso D., Martinez A., et al. Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod 69 (2006) 1034-1040
32. Renard C.E., Dailly E., David D.J.P., Hascoet M., and Bourin M. Monoamine metabolism changes following the mouse forced swim test but not the tail suspension test. Fundam Clin Pharmacol 17 (2003) 449-455
33. Sipkema D., Franssen M.C.R., Osinga R., Tramper J., and Wijffels R.H. Marine sponges as pharmacy. Mar Biotechnol 7 (2005) 142-162
34. Society for Neuroscience. In: Carey J. (Ed). Brain facts: a primer on the brain and nervous system. 4th ed (2002), Society for Neuroscience, Washington, DC 32
35. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
36. Thierry B., Steru L., Simon P., and Porsolt R.D. The tail suspension test: ethical considerations. Psychopharmacology 90 (1986) 284-285
37. Wells K.B., Stewart A., Hays R.D., Burnam M.A., Rogers W., Daniels M., et al. The functioning and well-being of depressed patients. JAMA 262 (1989) 914-919
38. Wong M., and Lichinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2 (2001) 343-351
39. Yousaf M., Hammond N.L., Peng J., Wahyuono S., McIntosh K.A., Charman W.N., et al. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. J Med Chem 47 (2004) 3512-3517